Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein.

ABSTRACT:

Background

Therapeutic antibodies for the treatment of neurological disease show great potential, but their applications are rather limited due to limited brain exposure. The most well-studied approach to enhance brain influx of protein therapeutics, is receptor-mediated transcytosis (RMT) by targeting nutrient receptors to shuttle protein therapeutics over the blood-brain barrier (BBB) along with their endogenous cargos. While higher brain exposure is achieved with RMT, the timeframe is short due to rather fast brain clearance. Therefore, we aim to increase the brain half-life of antibodies by binding to myelin oligodendrocyte glycoprotein (MOG), a CNS specific protein.

Methods

Alpaca immunization with mouse/human MOG, and subsequent phage selections and screenings for MOG

SUBMITTER: Cuypers ML 

PROVIDER: S-EPMC11783731 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature